

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 July 2023 (27.07.2023)



(10) International Publication Number
WO 2023/141531 A3

(51) International Patent Classification:

C12N 9/22 (2006.01) C12N 15/86 (2006.01)
A61K 48/00 (2006.01) A61P 19/02 (2006.01)
C12N 15/113 (2010.01) A61P 29/00 (2006.01)

(21) International Application Number:

PCT/US2023/060939

(22) International Filing Date:

19 January 2023 (19.01.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/301,033 19 January 2022 (19.01.2022) US
63303479 26 January 2022 (26.01.2022) US
63/390,222 18 July 2022 (18.07.2022) US

(71) Applicant: **ORTHOBIO THERAPEUTICS, INC.**
[US/US]: 1300 N. Frontage Road W., Box 5937, Vail, CO
81657 (US).

(72) Inventors: **MILLETT, Peter, J.**; 975 Pilgrim Drive, Ed-
wards, CO 81632 (US). **RUSSELL, Iain, Alasdair**; 11
Headington Drive, Cambridge CB1 9HE (GB). **ALLEN,**

Matthew, J.; 33 High Street, Swaffham Bulbeck, Cambs
CB25 0HP (GB). **GENTSCH, George**; 12 Lents Way,
Cambridge CB4 1UA (GB).

(74) Agent: **ANTCZAK, Andrew, J.** et al.; Morgan Lewis &
Bockius LLP, 1701 Market Street, Philadelphia, PA 19103
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) Title: TRANSMEMBRANE RECEPTOR GENE EDITING

Canine IL1RAP gene architecture




FIG. 2A

(57) Abstract: Provided herein are compositions and methods for ablating intracellular signaling through specific cell surface receptors as means of treatment for various conditions of a pro- inflammatory character. In some aspects, the compositions and methods are to prevent the progression of osteoarthritis and other arthritides and to treat osteoarthritis and other arthritides in a mammalian joint. In some aspects, the compositions and method are for treating or preventing localized nociception, inflammation, degeneration, or morphological changes associated with back or spine conditions or disorders.

[Continued on next page]

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

07 December 2023 (07.12.2023)